22nd Century Group to Sell GVB Biopharma to Nevada Consortium

Business by 2FIRSTS.ai

Dec.15.2023

22nd Century Group to Sell GVB Biopharma to Nevada Consortium

22nd Century Group, Inc, a US biotechnology company, has announced the sale of its GVB Biopharma cannabis/narcotics business.

According to a report from Newsfile Corp on December 14, the American biotechnology company 22nd Century Group, Inc announced that it has obtained approval from its original creditor bank to sell its GVB Biopharma cannabis/narcotics business to a Nevada consortium affiliated with GVB employees (Specialty Acquisition Corporation). This transaction is expected to help 22nd Century Group reduce its existing debt of $5.2 billion.

Larry Firestone, Chairman and CEO of 22nd Century Group, stated, "We are pleased to further reduce debt in the process of obtaining approval from the bank. This represents significant progress in repaying the principal of our credit facilities by the third quarter of 2024.

As previously announced, the insurance funds from the fire incident at the company's Grass Valley manufacturing facility are expected to be used for further debt reduction. Currently, the company is claiming approximately $9 million, although the final amount received will depend on the resolution of the matter.

The transaction is expected to be formally completed in December 2023, subject to the usual closing conditions.

The 22nd Century Group, Inc. is an agricultural biotechnology company that focuses on harm reduction in tobacco, low nicotine tobacco, and improving health and well-being through plant technology.

References:

[1] 22nd Century Group's Senior Lender Approves Sale of Hemp/Cannabis Franchise on Improved Terms

Also Read:

[1] 22nd Century Group Inc's Stock Drops 12.26%, but Shows Recent Recovery

[2] 22nd Century Group Announces Exercise of Existing Warrants and Fundraising

[3] 22nd Century Group Appoints Lawrence Firestone as Chairman and CEO

[4] 22nd Century Group Inc Sells GVB Biopharma for $2.25 Million

#North America #United States #CBD

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

California DOJ Outlines Next Steps for Unflavored Tobacco List; Enforcement to Target “Obviously Flavored” Products

The California DOJ issued Information Bulletin No. 2025-DLE-17 on November 10, 2025, providing an update on the state’s flavored tobacco enforcement. The Attorney General’s office is set to launch the Unflavored Tobacco List (UTL) by December 31, 2025, identifying tobacco products without characterizing flavors that may legally be sold in California. Enforcement will continue to focus on “obviously flavored” products, while unregistered products remain subject to seizure and penalties.

Nov.17 by 2FIRSTS.ai

Russian State Duma Passes Ban on Tobacco and Vape Sales at Public Transport Stops

Russia’s State Duma has approved, in its third reading, a law banning the sale of cigarettes and electronic cigarettes at public transport stops. The measure expands existing restrictions on tobacco sales at transport infrastructure facilities and aims to reduce accessibility, particularly among young people. The law includes an exemption for small settlements where such kiosks are the only sales points and will take effect on September 1, 2026.

Dec.18 by 2FIRSTS.ai

2Firsts Observation｜VELO at Stockholm Arlanda: Travel-Centric Messaging and Full-Line Flavour Presentation

2Firsts observed at Stockholm Arlanda Airport that British American Tobacco’s VELO positions the airport environment as a core marketing scenario, deploying large-format LED displays, a full flavour matrix, and clear nicotine-strength segmentation. The brand also features an instructional “How to Use VELO” section and multi-pack sales strategy, showcasing its systematic merchandising capabilities in the Nordic travel-retail channel.

Nov.19 by 2FIRSTS.ai

AG Miyares Argues Vape Ban Consistent with Federal Law, Seeks Dismissal

Virginia Attorney General Jason Miyares and Tax Commissioner James J. Alex have asked a federal court to dismiss a lawsuit challenging the state’s ban on flavored e-cigarettes. They argue plaintiffs lack standing because the products are already illegal under federal law. The state denies claims of federal preemption and asserts sovereign immunity, maintaining that its ban aligns with its authority to protect public health.